山东新华医疗器械股份有限公司关于公司控股股东增持公司股份计划的公告

Group 1 - The controlling shareholder of Shandong Xinhua Medical Instrument Co., Ltd. plans to increase its stake in the company, currently holding 175,385,227 shares, which accounts for 28.91% of the total share capital of 606,677,919 shares [2][3] - The increase plan aims to invest no less than RMB 100 million and no more than RMB 200 million within 12 months through the Shanghai Stock Exchange [2][3] - If the shareholding ratio reaches or exceeds 30%, the controlling shareholder will apply to the China Securities Regulatory Commission for exemption from making a tender offer [2][4] Group 2 - A subsidiary of the company has received a Class III medical device registration certificate for a dialysis fluid filter, which is designed to remove endotoxins, bacteria, and insoluble particles from dialysis fluid [7][8] - The product has a filtration rate of ≥1000 ml/min and meets strict microbial and endotoxin removal standards, enhancing the safety and quality of dialysis treatment [9] - The introduction of this product enriches the company's blood purification product line, potentially improving its core competitiveness in the market [9]